U.S. gives curtsy to Eli Lilly’s mind board test

<p>WASHINGTON (Reuters) – U.S. regulators gave a curtsy to an imaging exam from <span>Eli Lilly</span> and Co. that can for a initial time assistance <span>doctors</span> detect mind board tied to Alzheimer’s disease, a association said.</p>
<p> The <span>U.S. Food and Drug Administration</span> authorized a hot dye, called Amyvid, to assistance doctors order out either patients have Alzheimer’s, a many common form of dementia, Lilly announced late on Friday.</p>
<p> The color binds to clumps of a poisonous protein called beta amyloid that accumulates in a smarts of patients with Alzheimer’s. Doctors can afterwards see a board light adult on a atom glimmer tomography, or PET, scan.</p>
<p> Patients with Alzheimer’s always have some mind plaque, so a deficiency in a exam would tell doctors to demeanour for other causes of mental decline, such as basin or medications, Lill...